Objective:To modify the structure and evaluate the vasorelaxing function of natriuretic peptides . Methods :According to the structure‐activity relationship of natural natriuretic peptides (NPs) ,7 kinds of novel NPs (CNAAC 、BNAAC 、BNBAC 、ANCAC 、ANBAC 、BNCAC 、CNBAC) were artificially designed and engineered .Furthermore , perfusion experiments of in vitro blood vessels were performed to evaluate the vasorelaxing effects of these novel NPs ,com‐pared with the natural NPs including atrial natriuretic peptide (ANP) ,brain natriuretic peptide (BNP) ,and C type natri‐uretic peptide(CNP) .Results :Vasorelaxing effects were ranked as :CNP > CNAAC > BNAAC > BNBAC > ANCAC > ANP> BNP > ANBAC > BNCAC > CNBAC .Conclusion :Innovative designed NPs have the activity of their parent molecules ,and might be new candidate drugs against cardiovascular diseases .%目的：对天然的钠尿肽（NPs）分子进行改造，并比较新型 NPs 分子的舒血管效应。方法：根据天然 NPs 的构效关系，人工设计合成了7种新型的 NPs 分子：CN AAC 、BN AAC 、BN BAC 、A N CAC 、AN BAC 、BN CAC 、CN BAC 。进而采用离体血管灌流实验评价新型 NPs 的血管舒张活性，并与天然钠尿肽 ANP 、BNP 、CNP 进行比较。结果：血管舒张活性排序为：CNP ＞ CN AAC ＞ BN AAC ＞ BN BAC ＞ A N CAC ＞ ANP ＞ BNP ＞ A N BAC ＞ BN CAC ＞ CN BAC 。结论：新型设计的 NPs 具有其亲本分子的活性，可能成为治疗心血管疾病的新型候选药物。
展开▼
